ReviewFrontiers in immunology2025
PLK1 in cancer therapy: a comprehensive review of immunomodulatory mechanisms and therapeutic opportunities.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Chromosomal instability in cancer: sources, consequences and new therapeutic opportunities.Signal transduction and targeted therapy · 2026Review
- A versatile VLP-mediated CRISPR-RNP platform for precise genome editing and durable epigenome silencing in cancer.Molecular therapy. Nucleic acids · 2026Article
- Targeting MYC-Driven Cancers: From Oncogenic Addiction to Therapeutic Vulnerability.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Advancements of mRNA-lipid nanoparticle links to gene editing and immune responses.Journal, genetic engineering & biotechnology · 2026Review
- A tailored in vivo CRISPR screen identifies BAP1 as a potent tumor suppressor of sarcoma.JCI insight · 2026Article
- Targeting VAMP5 suppresses PLK1-driven growth of gliomas with high NDRG4 expression.Journal of neuro-oncology · 2026Article
- Mitotic Machinery Dysregulation in Lung Cancer: Biological Roles, Therapeutic Targeting, and Combination Strategies.Pharmaceutics · 2026Review
- MYC at the tumor-immune interface: mechanisms of immune escape and immunotherapy resistance.Frontiers in immunology · 2026Review
- N-Degron-Based PROTAC Targeting PLK1: A Potential Therapeutic Strategy for Cervical Cancer.Pharmaceutics · 2025Article
- Functional and structural impacts of oncogenic missense variants on human polo-like kinase 1 protein.Frontiers in bioinformatics · 2025Article
- Stemness- and hypoxia-based prognostic stratification index reveals G6PD as a regulator of hypoxia-driven stemness in hepatocellular carcinoma.Frontiers in immunology · 2025Article
- Inhibition of Plk1 Attenuates Downregulation of Water and Sodium Transporters in Obstructive Nephropathy.Kidney diseases (Basel, Switzerland)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PLK1 plays a crucial role in cell cycle regulation and cancer development, and its dysregulation has been implicated in the prognosis of a variety of malignancies. The potential of PLK1 inhibitors as cancer therapeutics has been extensively investigated. However, the underlying biology and mechanisms of PLK1 remain incompletely understood. In recent years, numerous studies have demonstrated that PLK1 overexpression is associated with resistance to certain chemotherapeutic agents, while its inhibition can enhance the efficacy of chemotherapy. In addition, PLK1 inhibitors have been shown to selectively target cancer cells as radiation sensitizers and exert synergistic effects in combination immunotherapy. The underlying mechanisms may involve the regulation of multiple immune cells and inflammatory factors, as well as alterations in the tumor microenvironment, ultimately influencing tumor genesis, migration, and invasion. Moreover, PLK1 can regulate the expression of immune checkpoint-related proteins, thereby playing a synergistic role in cancer therapy. Furthermore, PLK1 represents a promising target antigen for cancer immunotherapy, with potential applications in optimizing cancer vaccines. Therefore, this review focuses on the applications and underlying mechanisms of PLK1 in tumor immunotherapy, aiming to provide new insights for improving patient outcomes and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.